Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBRA: Novel combinations in advanced or metastatic NSCLC
jRCT2051250123Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label trial of rilvegostomig, ramucirumab and datopotamab deruxtecan in non-small cell lung cancer (NSCLC) (5 arms), sponsored by AstraZeneca. Primary endpoints: Number of participants with adverse events (AE) and serious adverse events (SAE) and Objective response rate (ORR). Started Oct 2025; status: recruiting.
02
Drugs
rilvegostomigramucirumabdatopotamab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2051250123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250123.